GlassScriptPhysician profile
Marcel B Twahirwa
NPI 1841381167
$80,963.33
in general payments reported to CMS, 2019-2025
16 companies · $132 in 2025
The $132 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54K · 2020: $19K · 2021: $4,320 · 2022: $3,601 · 2023: $173 · 2024: $102 · 2025: $132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $347 · Gift: $59.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $346.95 |
| Gift | $59.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $27,228.47 | 2019-2024 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $21,245.71 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14,661.72 | 2019-2022 | |
| Lilly USA, LLC | $10,851.41 | 2019-2025 | Zepbound, Mounjaro |
| Merck Sharp & Dohme LLC | $3,773.15 | 2019 | |
| Mannkind Corporation | $2,867.07 | 2019-2023 | Afrezza |
| Dexcom, INC. | $154.25 | 2023-2025 | Dexcom G6 Transmitter |
| Ultragenyx Pharmaceutical INC. | $96.42 | 2019-2022 | |
| Abbott Laboratories | $42.60 | 2025 | Freestyle Libre |
| Tandem Diabetes Care, INC. | $28.64 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Amgen INC. | $13.89 | 2022 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcel Twahirwa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.